Vnitr Lek 1996, 42(10):717-723

[Fundamentals of hospital treatment in exacerbations of chronic obstructive lung disease].

J Musil, V Vondra: Oddĕlení TRN FN, Praha.

Treatment of Acute Exacerbations of Chronic Obstructive Lung Disease Involves Administration of O2, beta 2 adrenergic, anticholinergic drugs, corticoids, theophylline, antibiotics, mucolytics and supported ventilation. The objective of oxygen treatment is to increase the oxygen saturation to a minimum of 90%, PaO2 = 8 kPa, without an increase of PaCO2 by more than 1.33 kPa or a reduction of the pH below 7.25. Beta 2 adrenergic substances are the most potent bronchodilatating agents. Inhalation of the preparation in solution is optimal. Neither the interval of administration nor the dosage are uniform. In Europe most frequently the following solutions are recommended: salbutamol (Ventolin) 0.5%-2.5 mg. This dose can be repeated, depending on tolerance, after 30-60 minutes, fenoterol (Berotec) 0.1%, most frequently an initial dose of 0.5-1.25 mg is used. In chronic obstructive lung disease inhalation of ipratropium in solution is preferred (Atrovent) 0.025%. American authors agreed on 0.5 mg after 4-8 hour intervals. A combination of adrenergic and cholinergic agents is useful as each drug acts by a different mechanism. The effect can potentiate while no undesirable effects develop. Views on corticoid administration in chronic obstructive lung disease differ. Some investigations did not prove a positive effect while others did. In the authors' department preference is given to the intravenous administration of 160 mg methylprednisolone divided into two doses per day. Intravenous administration of aminophylline is indicated if inhalation treatment is not effective enough or if inhalation treatment cannot be administered. Aminophylline is administered continually or intermittently in infusion, the dose for adults being 0.5-0.9 mg/kg/hour. Opinions on antibiotics differ. Some authors recommend them, others do not. The objective of antibiotic treatment is to shorten the duration of the exacerbation and to prevent deterioration in a patient with a minimal respiratory reserve. As to mucolytics, most frequently inhalatory forms of Bromhexine, Ambroxol, N-acetylcysteine and Mistabrone are used.